ADA Standards of Care in Diabetes—2024 Guideline

The American Diabetes Association (ADA) has recently released the Standards of Care in Diabetes—2024, offering comprehensive guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest research. The update includes recommendations on obesity drugs, screening practices, diabetes technology, and the use of teplizumab.

Notable changes involve managing obesity, screening for heart failure and peripheral arterial disease, and guidance on teplizumab and new obesity medications. The guidelines also focus on hypoglycemia prevention, screening for nonalcoholic fatty liver disease, and attention to diabetes-specific risk factors for fracture. Emphasis is placed on mastering diabetes technology and addressing the possible association between COVID-19 and new-onset type 1 diabetes. Other updates cover immunization, cultural sensitivity, psychosocial screening, and the importance of diabetes technology.

You must be healthcare professional to view this content.

POMConnect Banner2 Email Bottom